Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1439)	10/10/2005 1:05:20 PM
From: manny t	Read Replies (1) \| Respond to of 3722

BCRX, A possible takeover play? BioCryst Pharm: JMP discusses possible M&A plays on avian flu theme (12.35 +0.70) -Update- JMP Securities says that after GSK's purchase of IDBE, they view MEDI and CHIR as the only acquirable companies with a flu vaccine. CHIR has not yet resolved its flu vaccine manufacturing issues and firm does not know if the co has an avian flu vaccine in the works yet. While MEDI could potentially be an acquisition candidate, firm says FluMist is still a relatively small part of its overall business so any potential acquirer would have to be interested in the rest of MEDI's product portfolio as well. Firm says GSK and Roche are too big to be bought for their flu drugs, and Roche is unlikely to purchase GILD simply to avoid paying a royalty on Tamiflu sales. Firm notes that BCRX has a development-stage product which was shelved, but could potentially be revived. The stock was up over 13% last Friday on speculation that it might resume development of its flu drug, and firm thinks it is possible that a larger co could decide to acquire BCRX to get access to its flu drug candidate